{"transactions":[{"id":741349,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:21:06.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":3318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":3318,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":3318},"source":{"system":"sec-edgar","filing":"0001193125-26-267605","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267605/ownership.xml","form_type":"4"}},{"id":741348,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:21:06.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-26-267605","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267605/ownership.xml","form_type":"4"}},{"id":915786,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T23:10:28.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":961700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":961700,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":961700},"source":{"system":"sec-edgar","filing":"0001604457-26-000007","document":"form4-02062026_110224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000007/form4-02062026_110224.xml","form_type":"4"}},{"id":915785,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T23:10:28.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":274800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":274800,"derivative":{"underlying":"Common Stock","underlying_shares":274800},"source":{"system":"sec-edgar","filing":"0001604457-26-000007","document":"form4-02062026_110224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000007/form4-02062026_110224.xml","form_type":"4"}},{"id":917412,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T21:45:57.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":63475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":190425,"derivative":{"underlying":"Common Stock","underlying_shares":63475},"source":{"system":"sec-edgar","filing":"0001604457-26-000005","document":"form4-02052026_090254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000005/form4-02052026_090254.xml","form_type":"4"}},{"id":917411,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-05T21:45:57.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":18611,"price":3.47,"value":64580.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1543886,"source":{"system":"sec-edgar","filing":"0001604457-26-000005","document":"form4-02052026_090254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000005/form4-02052026_090254.xml","form_type":"4"}},{"id":917410,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-05T21:45:57.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":63475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1562497,"source":{"system":"sec-edgar","filing":"0001604457-26-000005","document":"form4-02052026_090254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000005/form4-02052026_090254.xml","form_type":"4"}},{"id":950265,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:32:24.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":29150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":30034,"derivative":{"underlying":"Common Stock","underlying_shares":29150},"source":{"system":"sec-edgar","filing":"0001604457-26-000003","document":"form4-01052026_090114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000003/form4-01052026_090114.xml","form_type":"4"}},{"id":950264,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:32:24.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":9952,"price":2.88,"value":28661.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1499022,"source":{"system":"sec-edgar","filing":"0001604457-26-000003","document":"form4-01052026_090114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000003/form4-01052026_090114.xml","form_type":"4"}},{"id":950263,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:32:24.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":29150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1508974,"source":{"system":"sec-edgar","filing":"0001604457-26-000003","document":"form4-01052026_090114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000003/form4-01052026_090114.xml","form_type":"4"}},{"id":1113013,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:36:38.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":2413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2413,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":2413},"source":{"system":"sec-edgar","filing":"0000950170-25-085489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085489/ownership.xml","form_type":"4"}},{"id":1113012,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:36:38.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":62728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":62728,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":62728},"source":{"system":"sec-edgar","filing":"0000950170-25-085489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085489/ownership.xml","form_type":"4"}},{"id":1158686,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2025-05-05T20:20:04.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-25-011955","document":"form4-05052025_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925011955/form4-05052025_040501.xml","form_type":"4"}},{"id":1158685,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-05-05T20:20:04.000Z","date":"2025-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2975,"price":1.38,"value":4105.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1479824,"source":{"system":"sec-edgar","filing":"0001415889-25-011955","document":"form4-05052025_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925011955/form4-05052025_040501.xml","form_type":"4"}},{"id":1158684,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-05-05T20:20:04.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1482799,"source":{"system":"sec-edgar","filing":"0001415889-25-011955","document":"form4-05052025_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925011955/form4-05052025_040501.xml","form_type":"4"}},{"id":1178884,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2025-04-03T20:15:20.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":9467,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-25-009937","document":"form4-04032025_040410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925009937/form4-04032025_040410.xml","form_type":"4"}},{"id":1178883,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-04-03T20:15:20.000Z","date":"2025-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3042,"price":1.48,"value":4502.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1473332,"source":{"system":"sec-edgar","filing":"0001415889-25-009937","document":"form4-04032025_040410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925009937/form4-04032025_040410.xml","form_type":"4"}},{"id":1178882,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-04-03T20:15:20.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1476374,"source":{"system":"sec-edgar","filing":"0001415889-25-009937","document":"form4-04032025_040410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925009937/form4-04032025_040410.xml","form_type":"4"}},{"id":1226583,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T21:15:20.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":false,"shares":9466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":18934,"derivative":{"underlying":"Common Stock","underlying_shares":9466},"source":{"system":"sec-edgar","filing":"0001415889-25-006496","document":"form4-03042025_040312.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925006496/form4-03042025_040312.xml","form_type":"4"}},{"id":1226582,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-04T21:15:20.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3277,"price":1.99,"value":6521.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1466907,"source":{"system":"sec-edgar","filing":"0001415889-25-006496","document":"form4-03042025_040312.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925006496/form4-03042025_040312.xml","form_type":"4"}},{"id":1226581,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-04T21:15:20.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":true,"shares":9466,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1470184,"source":{"system":"sec-edgar","filing":"0001415889-25-006496","document":"form4-03042025_040312.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925006496/form4-03042025_040312.xml","form_type":"4"}},{"id":1283844,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-04T21:15:15.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":888800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":888800,"derivative":{"exercise_price":2.4,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":888800},"source":{"system":"sec-edgar","filing":"0001415889-25-002941","document":"form4-02042025_040208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002941/form4-02042025_040208.xml","form_type":"4"}},{"id":1283843,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T21:15:15.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":253900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":253900,"derivative":{"underlying":"Common Stock","underlying_shares":253900},"source":{"system":"sec-edgar","filing":"0001415889-25-002941","document":"form4-02042025_040208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002941/form4-02042025_040208.xml","form_type":"4"}},{"id":1283842,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T21:15:15.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":28400,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-25-002941","document":"form4-02042025_040208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002941/form4-02042025_040208.xml","form_type":"4"}},{"id":1283841,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2025-02-04T21:15:15.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3559,"price":2.48,"value":8826.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1460718,"source":{"system":"sec-edgar","filing":"0001415889-25-002941","document":"form4-02042025_040208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002941/form4-02042025_040208.xml","form_type":"4"}},{"id":1283840,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2025-02-04T21:15:15.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1464277,"source":{"system":"sec-edgar","filing":"0001415889-25-002941","document":"form4-02042025_040208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002941/form4-02042025_040208.xml","form_type":"4"}},{"id":1313666,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T23:25:05.000Z","date":"2025-01-02","kind":"exercise","planned":false,"acquired":false,"shares":29149,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":59184,"derivative":{"underlying":"Common Stock","underlying_shares":29149},"source":{"system":"sec-edgar","filing":"0001415889-25-000621","document":"form4-01032025_060101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000621/form4-01032025_060101.xml","form_type":"4"}},{"id":1313665,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T23:25:05.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":88333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":88333,"derivative":{"underlying":"Common Stock","underlying_shares":88333},"source":{"system":"sec-edgar","filing":"0001415889-25-000621","document":"form4-01032025_060101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000621/form4-01032025_060101.xml","form_type":"4"}},{"id":1313664,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T23:25:05.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":37867,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-25-000621","document":"form4-01032025_060101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000621/form4-01032025_060101.xml","form_type":"4"}},{"id":1313663,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:05.000Z","date":"2025-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":13532,"price":2.48,"value":33559.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1454810,"source":{"system":"sec-edgar","filing":"0001415889-25-000621","document":"form4-01032025_060101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000621/form4-01032025_060101.xml","form_type":"4"}},{"id":1313662,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:05.000Z","date":"2025-01-02","kind":"exercise","planned":false,"acquired":true,"shares":29149,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1468342,"source":{"system":"sec-edgar","filing":"0001415889-25-000621","document":"form4-01032025_060101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000621/form4-01032025_060101.xml","form_type":"4"}},{"id":1313661,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:05.000Z","date":"2025-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3904,"price":2.48,"value":9681.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1439193,"source":{"system":"sec-edgar","filing":"0001415889-25-000621","document":"form4-01032025_060101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000621/form4-01032025_060101.xml","form_type":"4"}},{"id":1313660,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:05.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1443097,"source":{"system":"sec-edgar","filing":"0001415889-25-000621","document":"form4-01032025_060101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000621/form4-01032025_060101.xml","form_type":"4"}},{"id":1340181,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-06T21:15:10.000Z","date":"2024-12-04","kind":"exercise","planned":false,"acquired":false,"shares":118840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.52,"expiration_date":"2024-12-07","underlying":"Common Stock","underlying_shares":118840},"source":{"system":"sec-edgar","filing":"0001415889-24-028466","document":"form4-12062024_041206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924028466/form4-12062024_041206.xml","form_type":"4"}},{"id":1340180,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2024-12-06T21:15:10.000Z","date":"2024-12-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":68343,"price":3.76,"value":256969.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the exercise price and the Reporting Person's tax withholding obligations in connection with the option exercise described in this Form 4."}],"balance_after":1433630,"source":{"system":"sec-edgar","filing":"0001415889-24-028466","document":"form4-12062024_041206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924028466/form4-12062024_041206.xml","form_type":"4"}},{"id":1340179,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2024-12-06T21:15:10.000Z","date":"2024-12-04","kind":"exercise","planned":false,"acquired":true,"shares":118840,"price":1.52,"value":180636.8,"ownership":{"direct":true},"balance_after":1501973,"source":{"system":"sec-edgar","filing":"0001415889-24-028466","document":"form4-12062024_041206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924028466/form4-12062024_041206.xml","form_type":"4"}},{"id":1344469,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Restricted Stock Units","published_at":"2024-12-03T21:15:11.000Z","date":"2024-12-01","kind":"exercise","planned":false,"acquired":false,"shares":9466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":47334,"derivative":{"underlying":"Common Stock","underlying_shares":9466},"source":{"system":"sec-edgar","filing":"0001415889-24-028074","document":"form4-12032024_041203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924028074/form4-12032024_041203.xml","form_type":"4"}},{"id":1344468,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2024-12-03T21:15:11.000Z","date":"2024-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2721,"price":4.07,"value":11074.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1383133,"source":{"system":"sec-edgar","filing":"0001415889-24-028074","document":"form4-12032024_041203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924028074/form4-12032024_041203.xml","form_type":"4"}},{"id":1344467,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2024-12-03T21:15:11.000Z","date":"2024-12-01","kind":"exercise","planned":false,"acquired":true,"shares":9466,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1385854,"source":{"system":"sec-edgar","filing":"0001415889-24-028074","document":"form4-12032024_041203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924028074/form4-12032024_041203.xml","form_type":"4"}},{"id":1375049,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-11-05T21:20:05.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":56800,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-24-026138","document":"form4-11052024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924026138/form4-11052024_041101.xml","form_type":"4"}},{"id":1375048,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-11-05T21:20:05.000Z","date":"2024-11-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2721,"price":2.09,"value":5686.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1376388,"source":{"system":"sec-edgar","filing":"0001415889-24-026138","document":"form4-11052024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924026138/form4-11052024_041101.xml","form_type":"4"}},{"id":1375047,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-11-05T21:20:05.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1379109,"source":{"system":"sec-edgar","filing":"0001415889-24-026138","document":"form4-11052024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924026138/form4-11052024_041101.xml","form_type":"4"}},{"id":1391526,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-10-03T20:15:09.000Z","date":"2024-10-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":66267,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-24-024608","document":"form4-10032024_041004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924024608/form4-10032024_041004.xml","form_type":"4"}},{"id":1391525,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-10-03T20:15:09.000Z","date":"2024-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2722,"price":1.18,"value":3211.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1369642,"source":{"system":"sec-edgar","filing":"0001415889-24-024608","document":"form4-10032024_041004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924024608/form4-10032024_041004.xml","form_type":"4"}},{"id":1391524,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-10-03T20:15:09.000Z","date":"2024-10-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1372364,"source":{"system":"sec-edgar","filing":"0001415889-24-024608","document":"form4-10032024_041004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924024608/form4-10032024_041004.xml","form_type":"4"}},{"id":1415246,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-09-04T21:08:19.000Z","date":"2024-09-01","kind":"exercise","planned":false,"acquired":false,"shares":9466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":75734,"derivative":{"underlying":"Common Stock","underlying_shares":9466},"source":{"system":"sec-edgar","filing":"0001415889-24-022794","document":"form4-09042024_080935.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924022794/form4-09042024_080935.xml","form_type":"4"}},{"id":1415245,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-09-04T21:08:19.000Z","date":"2024-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2722,"price":1.18,"value":3211.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1362897,"source":{"system":"sec-edgar","filing":"0001415889-24-022794","document":"form4-09042024_080935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924022794/form4-09042024_080935.xml","form_type":"4"}},{"id":1415244,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-09-04T21:08:19.000Z","date":"2024-09-01","kind":"exercise","planned":false,"acquired":true,"shares":9466,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1365619,"source":{"system":"sec-edgar","filing":"0001415889-24-022794","document":"form4-09042024_080935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924022794/form4-09042024_080935.xml","form_type":"4"}},{"id":1434512,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-08-13T20:15:05.000Z","date":"2024-08-09","kind":"exercise","planned":false,"acquired":false,"shares":43548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.72,"expiration_date":"2024-08-12","underlying":"Common Stock","underlying_shares":43548},"source":{"system":"sec-edgar","filing":"0001415889-24-021154","document":"form4-08132024_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924021154/form4-08132024_040801.xml","form_type":"4"}},{"id":1434511,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-08-13T20:15:05.000Z","date":"2024-08-09","kind":"exercise","planned":false,"acquired":true,"shares":43548,"price":0.72,"value":31354.56,"ownership":{"direct":true},"balance_after":1356153,"source":{"system":"sec-edgar","filing":"0001415889-24-021154","document":"form4-08132024_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924021154/form4-08132024_040801.xml","form_type":"4"}},{"id":1440420,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-08-05T20:15:18.000Z","date":"2024-08-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":85200,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-24-020740","document":"form4-08052024_040814.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924020740/form4-08052024_040814.xml","form_type":"4"}},{"id":1440419,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-08-05T20:15:18.000Z","date":"2024-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2722,"price":1.32,"value":3593.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1312605,"source":{"system":"sec-edgar","filing":"0001415889-24-020740","document":"form4-08052024_040814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924020740/form4-08052024_040814.xml","form_type":"4"}},{"id":1440418,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-08-05T20:15:18.000Z","date":"2024-08-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1315327,"source":{"system":"sec-edgar","filing":"0001415889-24-020740","document":"form4-08052024_040814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924020740/form4-08052024_040814.xml","form_type":"4"}},{"id":1459385,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-07-03T20:15:15.000Z","date":"2024-07-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":94667,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-24-019172","document":"form4-07032024_040707.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924019172/form4-07032024_040707.xml","form_type":"4"}},{"id":1459384,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-07-03T20:15:15.000Z","date":"2024-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2722,"price":1.15,"value":3130.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1305860,"source":{"system":"sec-edgar","filing":"0001415889-24-019172","document":"form4-07032024_040707.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924019172/form4-07032024_040707.xml","form_type":"4"}},{"id":1459383,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-07-03T20:15:15.000Z","date":"2024-07-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1308582,"source":{"system":"sec-edgar","filing":"0001415889-24-019172","document":"form4-07032024_040707.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924019172/form4-07032024_040707.xml","form_type":"4"}},{"id":1488148,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:36.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":1736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1736,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":1736},"source":{"system":"sec-edgar","filing":"0000950170-24-069888","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069888/ownership.xml","form_type":"4"}},{"id":1488147,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:36.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":40282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":40282,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":40282},"source":{"system":"sec-edgar","filing":"0000950170-24-069888","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069888/ownership.xml","form_type":"4"}},{"id":1491468,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-06-04T20:30:26.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":false,"shares":9466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":104134,"derivative":{"underlying":"Common Stock","underlying_shares":9466},"source":{"system":"sec-edgar","filing":"0001415889-24-015371","document":"form4-06042024_040622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924015371/form4-06042024_040622.xml","form_type":"4"}},{"id":1491467,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-06-04T20:30:26.000Z","date":"2024-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2722,"price":1.03,"value":2803.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1299115,"source":{"system":"sec-edgar","filing":"0001415889-24-015371","document":"form4-06042024_040622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924015371/form4-06042024_040622.xml","form_type":"4"}},{"id":1491466,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-06-04T20:30:26.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":true,"shares":9466,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1301837,"source":{"system":"sec-edgar","filing":"0001415889-24-015371","document":"form4-06042024_040622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924015371/form4-06042024_040622.xml","form_type":"4"}},{"id":1527509,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-05-03T20:20:08.000Z","date":"2024-05-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":113600,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-24-012167","document":"form4-05032024_040502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924012167/form4-05032024_040502.xml","form_type":"4"}},{"id":1527508,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-05-03T20:20:08.000Z","date":"2024-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2784,"price":1.26,"value":3507.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1292371,"source":{"system":"sec-edgar","filing":"0001415889-24-012167","document":"form4-05032024_040502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924012167/form4-05032024_040502.xml","form_type":"4"}},{"id":1527507,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-05-03T20:20:08.000Z","date":"2024-05-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1295155,"source":{"system":"sec-edgar","filing":"0001415889-24-012167","document":"form4-05032024_040502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924012167/form4-05032024_040502.xml","form_type":"4"}},{"id":1548676,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-04-03T21:00:44.000Z","date":"2024-04-01","kind":"exercise","planned":false,"acquired":false,"shares":9467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the\nPlan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be\nInterim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board\nof Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as\nInterim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":123067,"derivative":{"underlying":"Common Stock","underlying_shares":9467},"source":{"system":"sec-edgar","filing":"0001415889-24-010060","document":"form4-04032024_090431.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924010060/form4-04032024_090431.xml","form_type":"4"}},{"id":1548675,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-04-03T21:00:44.000Z","date":"2024-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3224,"price":1.26,"value":4062.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1285688,"source":{"system":"sec-edgar","filing":"0001415889-24-010060","document":"form4-04032024_090431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924010060/form4-04032024_090431.xml","form_type":"4"}},{"id":1548674,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-04-03T21:00:44.000Z","date":"2024-04-01","kind":"exercise","planned":false,"acquired":true,"shares":9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1288912,"source":{"system":"sec-edgar","filing":"0001415889-24-010060","document":"form4-04032024_090431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924010060/form4-04032024_090431.xml","form_type":"4"}},{"id":1594279,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T22:08:09.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":false,"shares":9466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":132534,"derivative":{"underlying":"Common Stock","underlying_shares":9466},"source":{"system":"sec-edgar","filing":"0001209191-24-004407","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004407/doc4.xml","form_type":"4"}},{"id":1594278,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President and CEO"}}],"security":"Common Stock","published_at":"2024-03-05T22:08:09.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3223,"price":1.24,"value":3996.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1279445,"source":{"system":"sec-edgar","filing":"0001209191-24-004407","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004407/doc4.xml","form_type":"4"}},{"id":1594277,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President and CEO"}}],"security":"Common Stock","published_at":"2024-03-05T22:08:09.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":true,"shares":9466,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1282668,"source":{"system":"sec-edgar","filing":"0001209191-24-004407","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004407/doc4.xml","form_type":"4"}},{"id":1658223,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Restricted Stock Units","published_at":"2024-02-06T00:36:52.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":142000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":142000,"derivative":{"underlying":"Common Stock","underlying_shares":142000},"source":{"system":"sec-edgar","filing":"0001209191-24-002842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124002842/doc4.xml","form_type":"4"}},{"id":1658222,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-06T00:36:52.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":497000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO."}],"balance_after":497000,"derivative":{"exercise_price":1.2,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":497000},"source":{"system":"sec-edgar","filing":"0001209191-24-002842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124002842/doc4.xml","form_type":"4"}},{"id":1797508,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-24T20:13:26.000Z","date":"2023-08-22","kind":"exercise","planned":false,"acquired":false,"shares":9604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.552,"expiration_date":"2023-09-07","underlying":"Common Stock","underlying_shares":9604},"source":{"system":"sec-edgar","filing":"0000950170-23-044379","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023044379/ownership.xml","form_type":"4"}},{"id":1797507,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-24T20:13:26.000Z","date":"2023-08-22","kind":"exercise","planned":false,"acquired":true,"shares":9604,"price":0.552,"value":5301.408,"ownership":{"direct":true},"balance_after":15854,"source":{"system":"sec-edgar","filing":"0000950170-23-044379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023044379/ownership.xml","form_type":"4"}},{"id":1835426,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:30:56.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":915,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":915},"source":{"system":"sec-edgar","filing":"0000950170-23-031775","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023031775/ownership.xml","form_type":"4"}},{"id":1835425,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:30:56.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":21222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":21222,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":21222},"source":{"system":"sec-edgar","filing":"0000950170-23-031775","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023031775/ownership.xml","form_type":"4"}},{"id":1971842,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-02","kind":"exercise","acquired":false,"shares":18254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023."}],"balance_after":18254,"derivative":{"underlying":"Common Stock","underlying_shares":18254},"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":1971841,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023."}],"balance_after":72000,"derivative":{"underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":1971840,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":18275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023."}],"balance_after":36550,"derivative":{"underlying":"Common Stock","underlying_shares":18275},"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":1971839,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":96150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":96150},"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":1971838,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":30240,"price":12.6346,"value":382070.304,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1273202,"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":1971837,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-02","kind":"exercise","acquired":true,"shares":18254,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1303442,"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":1971836,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":29000,"price":12.3651,"value":358587.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.88 to $12.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1285188,"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":1971835,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1314188,"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":1971834,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":18275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1290188,"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":1971833,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-04T01:37:20.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":96150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":1271913,"source":{"system":"sec-edgar","filing":"0001209191-23-016074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016074/doc4.xml","form_type":"4"}},{"id":2032195,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T22:09:17.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":200,"price":17.535,"value":3507.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.51 to $17.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"}],"balance_after":1175763,"source":{"system":"sec-edgar","filing":"0001209191-23-007032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123007032/doc4.xml","form_type":"4"}},{"id":2032194,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T22:09:17.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":3121,"price":16.8827,"value":52690.9067,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.51 to $17.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"}],"balance_after":1175963,"source":{"system":"sec-edgar","filing":"0001209191-23-007032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123007032/doc4.xml","form_type":"4"}},{"id":2032193,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T22:09:17.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":600,"price":15.5533,"value":9331.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.27 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"}],"balance_after":1179084,"source":{"system":"sec-edgar","filing":"0001209191-23-007032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123007032/doc4.xml","form_type":"4"}},{"id":2032192,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T22:09:17.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":1079,"price":14.5671,"value":15717.9009,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.25 to $15.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1179684,"source":{"system":"sec-edgar","filing":"0001209191-23-007032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123007032/doc4.xml","form_type":"4"}},{"id":2032191,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T22:09:17.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":25000,"price":16.747,"value":418675.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.28 to $17.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1180763,"source":{"system":"sec-edgar","filing":"0001209191-23-007032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123007032/doc4.xml","form_type":"4"}},{"id":2065862,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T23:20:05.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":15000,"price":14.8895,"value":223342.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.65 to $15.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1205763,"source":{"system":"sec-edgar","filing":"0001209191-23-001329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123001329/doc4.xml","form_type":"4"}},{"id":2065861,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T23:20:05.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":1618,"price":16.1594,"value":26145.9092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.92 to $16.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1220763,"source":{"system":"sec-edgar","filing":"0001209191-23-001329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123001329/doc4.xml","form_type":"4"}},{"id":2065860,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T23:20:05.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":23382,"price":15.1855,"value":355067.361,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.89 to $15.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1222381,"source":{"system":"sec-edgar","filing":"0001209191-23-001329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123001329/doc4.xml","form_type":"4"}},{"id":2237409,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T21:04:28.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":2319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2319,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":2319},"source":{"system":"sec-edgar","filing":"0000899243-22-021626","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322021626/doc4.xml","form_type":"4"}},{"id":2237408,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T21:04:28.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":53812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":53812,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":53812},"source":{"system":"sec-edgar","filing":"0000899243-22-021626","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322021626/doc4.xml","form_type":"4"}},{"id":2290971,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-25T21:13:04.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":20000,"price":15.1828,"value":303656.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1245763,"source":{"system":"sec-edgar","filing":"0001209191-22-025537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122025537/doc4.xml","form_type":"4"}},{"id":2290970,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-25T21:13:04.000Z","date":"2022-04-22","kind":"sale","acquired":false,"shares":25000,"price":15.0439,"value":376097.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1265763,"source":{"system":"sec-edgar","filing":"0001209191-22-025537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122025537/doc4.xml","form_type":"4"}},{"id":2290969,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-25T21:13:04.000Z","date":"2022-04-21","kind":"sale","acquired":false,"shares":25000,"price":15.2379,"value":380947.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1290763,"source":{"system":"sec-edgar","filing":"0001209191-22-025537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122025537/doc4.xml","form_type":"4"}},{"id":2334929,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-14T20:58:28.000Z","date":"2022-03-11","kind":"sale","acquired":false,"shares":56303,"price":15.9147,"value":896045.3541,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.72 to $16.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1315763,"source":{"system":"sec-edgar","filing":"0001209191-22-018516","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122018516/doc4.xml","form_type":"4"}}],"next_cursor":"2022-03-14T20:58:28.000000Z,2334929"}